A detailed history of Trexquant Investment LP transactions in Alector, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 102,463 shares of ALEC stock, worth $196,728. This represents 0.01% of its overall portfolio holdings.

Number of Shares
102,463
Previous 146,559 30.09%
Holding current value
$196,728
Previous $665,000 28.12%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.34 - $6.58 $191,376 - $290,151
-44,096 Reduced 30.09%
102,463 $478,000
Q2 2024

Aug 13, 2024

BUY
$4.19 - $6.23 $436,241 - $648,636
104,115 Added 245.3%
146,559 $665,000
Q1 2024

May 14, 2024

SELL
$5.69 - $8.08 $12,102 - $17,186
-2,127 Reduced 4.77%
42,444 $255,000
Q4 2023

Feb 09, 2024

SELL
$3.77 - $8.39 $15,837 - $35,246
-4,201 Reduced 8.61%
44,571 $355,000
Q3 2023

Nov 13, 2023

BUY
$5.2 - $8.77 $253,614 - $427,730
48,772 New
48,772 $316,000
Q1 2023

May 15, 2023

BUY
$5.85 - $9.84 $97,238 - $163,560
16,622 New
16,622 $102,000
Q2 2022

Aug 11, 2022

SELL
$7.65 - $14.24 $289,407 - $538,713
-37,831 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$13.02 - $20.78 $258,225 - $412,129
19,833 Added 110.2%
37,831 $539,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $25.54 $348,261 - $459,668
17,998 New
17,998 $372,000
Q3 2021

Nov 12, 2021

SELL
$21.65 - $39.49 $214,356 - $390,990
-9,901 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$15.5 - $22.48 $153,465 - $222,574
9,901 New
9,901 $206,000
Q4 2020

Feb 11, 2021

SELL
$9.4 - $16.7 $233,684 - $415,162
-24,860 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$10.54 - $24.96 $131,296 - $310,926
12,457 Added 100.44%
24,860 $262,000
Q2 2020

Aug 07, 2020

BUY
$21.87 - $33.11 $271,253 - $410,663
12,403 New
12,403 $303,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $159M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.